Discovery of new diaryl ether inhibitors against Mycobacterium tuberculosis targeting the minor portal of InhA.

[1]  Weiying Lin,et al.  Harnessing Dual-Fluorescence Lifetime Probes to Validate Regulatory Mechanisms of Organelle Interactions. , 2022, Journal of the American Chemical Society.

[2]  M. Abdel-Aziz,et al.  Novel diaryl ether derivatives as InhA inhibitors: Design, synthesis and antimycobacterial activity. , 2022, Bioorganic chemistry.

[3]  Shi-wu Chen,et al.  Design, synthesis and biological evaluation of coumarin derivatives as potential BRD4 inhibitors. , 2022, Bioorganic chemistry.

[4]  L. Mourey,et al.  Drug screening approach against mycobacterial fatty acyl-AMP ligase FAAL32 renews the interest of the salicylanilide pharmacophore in the fight against tuberculosis. , 2022, Bioorganic & medicinal chemistry.

[5]  Le Pan,et al.  Design, Synthesis, and Antifungal Activity of 4-Amino Coumarin Based Derivatives , 2022, Molecules.

[6]  Fozia Batool,et al.  An Update on Synthesis of Coumarin Sulfonamides as Enzyme Inhibitors and Anticancer Agents , 2022, Molecules.

[7]  S. Bősze,et al.  Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity. , 2021, European journal of medicinal chemistry.

[8]  S. Bhakta,et al.  New InhA Inhibitors Based on Expanded Triclosan and Di-Triclosan Analogues to Develop a New Treatment for Tuberculosis , 2021, Pharmaceuticals.

[9]  T. Legigan,et al.  Synthesis and preliminary anticancer evaluation of new triazole bisphosphonate-based isoprenoid biosynthesis inhibitors. , 2021, European journal of medicinal chemistry.

[10]  A. Tiwari,et al.  Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents , 2020, Molecular Diversity.

[11]  Ehab S. Taher,et al.  In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors , 2020, Molecules.

[12]  Xianhai Lv,et al.  Novel coumarin-thiazolyl ester derivatives as potential DNA gyrase Inhibitors: Design, synthesis, and antibacterial activity. , 2020, Bioorganic chemistry.

[13]  D. Sriram,et al.  Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors. , 2020, European journal of medicinal chemistry.

[14]  S. Cole,et al.  Synthesis and Structure-Activity Relationship Studies of C2-Modified Analogs of the Antimycobacterial Natural Product Pyridomycin. , 2020, Journal of medicinal chemistry.

[15]  Jie Sun,et al.  Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer's disease agents. , 2019, Bioorganic & medicinal chemistry letters.

[16]  Pharit Kamsri,et al.  Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography , 2019, J. Chem. Inf. Model..

[17]  M. Pasca,et al.  First triclosan-based macrocyclic inhibitors of InhA enzyme. , 2019, Bioorganic chemistry.

[18]  M. Kariduraganavar,et al.  Click chemistry based regioselective one‐pot synthesis of coumarin‐3‐yl‐methyl‐1,2,3‐triazolyl‐1,2,4‐triazol‐3(4H)‐ones as newer potent antitubercular agents , 2019, Archiv der Pharmazie.

[19]  Mallika Alvala,et al.  Design and synthesis of 9H‐fluorenone based 1,2,3‐triazole analogues as Mycobacterium tuberculosis InhA inhibitors , 2018, Chemical biology & drug design.

[20]  A. Korkegian,et al.  Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA , 2018, Life Science Alliance.

[21]  A. Prasad,et al.  Synthesis and antimycobacterial activity of 1-(β-d-Ribofuranosyl)-4-coumarinyloxymethyl- / -coumarinyl-1,2,3-triazole. , 2018, European journal of medicinal chemistry.

[22]  M. Krátký,et al.  Triclosan and its derivatives as antimycobacterial active agents , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  L. Maveyraud,et al.  An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors. , 2018, European journal of medicinal chemistry.

[24]  P. Tonge,et al.  Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors. , 2017, Journal of the American Chemical Society.

[25]  M. Kulkarni,et al.  Design, synthesis and evaluation of diphenyl ether analogues as antitubercular agents , 2016 .

[26]  Christoph E. Dumelin,et al.  Discovery of cofactor-specific, bactericidal Mycobacterium tuberculosis InhA inhibitors using DNA-encoded library technology , 2016, Proceedings of the National Academy of Sciences.

[27]  E. J. North,et al.  Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3 , 2016, Antimicrobial Agents and Chemotherapy.

[28]  J. Sacchettini,et al.  Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor , 2016, EBioMedicine.

[29]  S. Bhakta,et al.  Design and Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-methylpiperazine (BM212) and N-Adamantan-2-yl-N'-((E)-3,7-dimethylocta-2,6-dienyl)ethane-1,2-diamine (SQ109) Pyrrole Hybrid Derivatives: Discovery of Potent Antitubercular Agents Effective against Multidrug-Resista , 2016, Journal of medicinal chemistry.

[30]  C. Supuran,et al.  Thioxocoumarins Show an Alternative Carbonic Anhydrase Inhibition Mechanism Compared to Coumarins. , 2016, Journal of medicinal chemistry.

[31]  M. Novič,et al.  In Silico Discovery of Novel Potent Antioxidants on the Basis of Pulvinic Acid and Coumarine Derivatives and Their Experimental Evaluation , 2015, PloS one.

[32]  Jana Korduláková,et al.  Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth. , 2015, European journal of medicinal chemistry.

[33]  M. García-Díaz,et al.  Rational Modulation of the Induced-Fit Conformational Change for Slow-Onset Inhibition in Mycobacterium tuberculosis InhA. , 2015, Biochemistry.

[34]  Zhijia Wang,et al.  Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents. , 2015, Journal of medicinal chemistry.

[35]  Paul W Smith,et al.  Direct inhibitors of InhA are active against Mycobacterium tuberculosis , 2015, Science Translational Medicine.

[36]  Shichun Lun,et al.  Biological Evaluation of Potent Triclosan‐Derived Inhibitors of the Enoyl–Acyl Carrier Protein Reductase InhA in Drug‐Sensitive and Drug‐Resistant Strains of Mycobacterium tuberculosis , 2014, ChemMedChem.

[37]  M. García-Díaz,et al.  Time‐Dependent Diaryl Ether Inhibitors of InhA: Structure–Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy , 2014, ChemMedChem.

[38]  K. Rissanen,et al.  Luminescent alkynyl-gold(I) coumarin derivatives and their biological activity. , 2014, Dalton transactions.

[39]  Peter J. Tonge,et al.  A Structural and Energetic Model for the Slow-Onset Inhibition of the Mycobacterium tuberculosis Enoyl-ACP Reductase InhA , 2014, ACS chemical biology.

[40]  Shahul Hameed,et al.  Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. , 2013, Journal of medicinal chemistry.

[41]  P. Brennan,et al.  A Common Mechanism of Inhibition of the Mycobacterium tuberculosis Mycolic Acid Biosynthetic Pathway by Isoxyl and Thiacetazone* , 2012, The Journal of Biological Chemistry.

[42]  S. Cole,et al.  Towards a new tuberculosis drug: pyridomycin – nature's isoniazid , 2012, EMBO molecular medicine.

[43]  Vinod Nair,et al.  SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[44]  Michael S. Scherman,et al.  INHIBITION OF MYCOLIC ACID TRANSPORT ACROSS THE MYCOBACTERIUM TUBERCULOSIS PLASMA MEMBRANE , 2011, Nature chemical biology.

[45]  D. Harrowven,et al.  Unified syntheses of cavicularin and riccardin C: addressing the synthesis of an arene adopting a boat configuration. , 2011, Chemistry.

[46]  Ramiz A. Boulos,et al.  Phosphonated calix[4]arene-based amphiphiles as scaffolds for fluorescent nano-fibres. , 2011, Chemical communications.

[47]  Clemens Vonrhein,et al.  Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.

[48]  Peter J Tonge,et al.  A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosis* , 2010, The Journal of Biological Chemistry.

[49]  Joel S. Freundlich,et al.  Triclosan Derivatives: Towards Potent Inhibitors of Drug‐Sensitive and Drug‐Resistant Mycobacterium tuberculosis , 2009, ChemMedChem.

[50]  Peter J. Tonge,et al.  Targeting Fatty Acid Biosynthesis for the Development of Novel Chemotherapeutics against Mycobacterium tuberculosis: Evaluation of A-Ring-Modified Diphenyl Ethers as High-Affinity InhA Inhibitors , 2007, Antimicrobial Agents and Chemotherapy.

[51]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[52]  Conrad C. Huang,et al.  Tools for integrated sequence-structure analysis with UCSF Chimera , 2006, BMC Bioinformatics.

[53]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[54]  Ian D. Williams,et al.  Ruthenium-catalyzed cycloaddition of alkynes and organic azides. , 2006, Journal of the American Chemical Society.

[55]  Peter J Tonge,et al.  High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. , 2006, ACS chemical biology.

[56]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[57]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[58]  David Alland,et al.  Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase , 2003, Journal of Biological Chemistry.

[59]  G. Besra,et al.  Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis , 2002, Molecular microbiology.

[60]  Luke G Green,et al.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. , 2002, Angewandte Chemie.

[61]  Morten Meldal,et al.  Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. , 2002, The Journal of organic chemistry.

[62]  S. Parikh,et al.  Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. , 2000, Biochemistry.

[63]  C. Vilchèze,et al.  Crystal Structure of the Mycobacterium tuberculosis Enoyl-ACP Reductase, InhA, in Complex with NAD+ and a C16 Fatty Acyl Substrate* , 1999, The Journal of Biological Chemistry.

[64]  J. D. Douglas,et al.  Antimycobacterial Activities of Isoxyl and New Derivatives through the Inhibition of Mycolic Acid Synthesis , 1999, Antimicrobial Agents and Chemotherapy.

[65]  J. Sacchettini,et al.  Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis , 1995, Science.

[66]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[67]  Gaoxue Wang,et al.  Synthesis and biological evaluation of coumarin derivatives containing imidazole skeleton as potential antibacterial agents. , 2018, European journal of medicinal chemistry.

[68]  Alexei Vagin,et al.  Molecular replacement with MOLREP. , 2010, Acta crystallographica. Section D, Biological crystallography.